Spotlight on Internal Medicine

Credits: 1.00 CME / MOC
Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control—Share, Learn, Engage: Setting and Achieving Treatment Targets in Systemic Lupus Erythematosus
Sheetal Desai, MD, MSEd
Forefront Collaborative

Systemic Lupus Erythematosus: Patient-Centered Care to Improve Disease Control—Share, Learn, Engage: Setting and Achieving Treatment Targets in Systemic Lupus Erythematosus

Start

Activity Details

Free CME/ABIM MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Part II Points
Released: April 9, 2021
Expires: April 9, 2022
60 minutes to complete

Accredited By

Target Audience

The primary target audience for the proposed initiative is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.

Learning Objectives

As a result of participation in this activity, participants should increase their ability to:

  • Utilize a treat-to-target approach to individualize treatment in patients with SLE.
  • Improve assessment of SLE disease activity and achievement of treatment goals.
  • Employ patient engagement strategies and shared decision making to discuss with patients their perceptions of disease, treatment goals, and benefit/risk profiles of SLE treatment options.

Activity Description

In this 60-minute activity, participants will improve their ability to assess systemic lupus erythematosus (SLE) disease activity and treatment outcomes by viewing presentations, engaging in a case study, and exploring various measures in a matching exercise. This activity will also help bridge the gap between patients’ perceptions of their disease and healthcare providers’ assessment. The SLE clinical expert and the patient will demonstrate effective patient engagement strategies—in particular, shared decision making using a decision aid—to achieve optimal, measurable therapeutic outcomes that advance care for patients living with SLE.

Faculty

Sheetal Desai, MD, MSEd
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California


Maria Dall’Era, MD
Professor and Chief, Division of Rheumatology
Jean S. Engleman Distinguished Professorship in Rheumatology,
Director, Lupus Clinic and Rheumatology Clinical Research Center
Department of Medicine
University of California, San Francisco
San Francisco, California

Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Marianna Shershneva, PhD, Megan Ragan
  • Presenters: Maria Dall’Era, MD, Aileen Olivares

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Presenter: Sheetal Desai, MD, MSEd
    • Advisory Board: Janssen, GlaxoSmithKline
    • Speakers Bureau: Janssen, GlaxoSmithKline

CME Content Review

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Activity Details

Free CME/ABIM MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Part II Points
Released: April 9, 2021
Expires: April 9, 2022
60 minutes to complete

Accredited By

Target Audience

The primary target audience for the proposed initiative is rheumatologists who practice in the United States (US) and outside the US. Other rheumatology providers and other clinicians who treat patients with systemic lupus erythematosus (SLE) can benefit from participation.

Learning Objectives

As a result of participation in this activity, participants should increase their ability to:

  • Utilize a treat-to-target approach to individualize treatment in patients with SLE.
  • Improve assessment of SLE disease activity and achievement of treatment goals.
  • Employ patient engagement strategies and shared decision making to discuss with patients their perceptions of disease, treatment goals, and benefit/risk profiles of SLE treatment options.

Activity Description

In this 60-minute activity, participants will improve their ability to assess systemic lupus erythematosus (SLE) disease activity and treatment outcomes by viewing presentations, engaging in a case study, and exploring various measures in a matching exercise. This activity will also help bridge the gap between patients’ perceptions of their disease and healthcare providers’ assessment. The SLE clinical expert and the patient will demonstrate effective patient engagement strategies—in particular, shared decision making using a decision aid—to achieve optimal, measurable therapeutic outcomes that advance care for patients living with SLE.

Faculty

Sheetal Desai, MD, MSEd
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California


Maria Dall’Era, MD
Professor and Chief, Division of Rheumatology
Jean S. Engleman Distinguished Professorship in Rheumatology,
Director, Lupus Clinic and Rheumatology Clinical Research Center
Department of Medicine
University of California, San Francisco
San Francisco, California

Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Marianna Shershneva, PhD, Megan Ragan
  • Presenters: Maria Dall’Era, MD, Aileen Olivares

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Presenter: Sheetal Desai, MD, MSEd
    • Advisory Board: Janssen, GlaxoSmithKline
    • Speakers Bureau: Janssen, GlaxoSmithKline

CME Content Review

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

ACCME: Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™; physicians should claim only the creditcommensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Internal Medicine Presentations

0.25 CME / CNE
Postgraduate Institute for Medicine
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series – Module 8: Implicit Bias and Racial Disparities

Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series – Module 8: Implicit Bias and Racial Disparities

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: January 14, 2022
Expires: January 14, 2023
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

  • Incorporate strategies to improve equity in care across patient populations

Activity Description

Many patients of color face implicit bias or discrimination in health care, including HIV care. This can result in lower levels of adherence and viral suppression as well as a lack of equity in health care. It is important for clinicians to recognize their own biases and those that exist in their practice in order to provide equitable care for patients of color. Dr. David Malebranche and Dr. Oni Blackstock discuss a patient who has faced implicit bias and a lack of equity at another provider’s practice. They discuss the dangers of implicit bias, strategies to recognize it, opportunities to achieve equitable care, and both individual and clinic-level changes that can reduce implicit bias.

Faculty

David Malebranche, MD, MPH
Internal Medicine Physician
Sexual Health/HIV Expert
Atlanta, Georgia

Oni Blackstock, MD, MHS
Founder and Executive Director
Health Justice
New York, New York

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

David Malebranche, MD, MPH: Consulting Fees: Gilead Sciences, Inc., ViiV Healthcare Limited; Speakers’ Bureaus: Gilead Sciences, Inc.

Oni Blackstock, MD, MHS: Nothing to disclose

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at [email protected] or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at [email protected]

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: January 14, 2022
Expires: January 14, 2023
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

  • Incorporate strategies to improve equity in care across patient populations

Activity Description

Many patients of color face implicit bias or discrimination in health care, including HIV care. This can result in lower levels of adherence and viral suppression as well as a lack of equity in health care. It is important for clinicians to recognize their own biases and those that exist in their practice in order to provide equitable care for patients of color. Dr. David Malebranche and Dr. Oni Blackstock discuss a patient who has faced implicit bias and a lack of equity at another provider’s practice. They discuss the dangers of implicit bias, strategies to recognize it, opportunities to achieve equitable care, and both individual and clinic-level changes that can reduce implicit bias.

Faculty

David Malebranche, MD, MPH
Internal Medicine Physician
Sexual Health/HIV Expert
Atlanta, Georgia

Oni Blackstock, MD, MHS
Founder and Executive Director
Health Justice
New York, New York

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

David Malebranche, MD, MPH: Consulting Fees: Gilead Sciences, Inc., ViiV Healthcare Limited; Speakers’ Bureaus: Gilead Sciences, Inc.

Oni Blackstock, MD, MHS: Nothing to disclose

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at [email protected] or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at [email protected]

0.5 CME / CNE
Medical Education Resources (MER)
Paths to Functional Recovery in Major Depressive Disorder: Putting the Patient First – Combining Patient-Centered Care for Major Depressive Disorder with the Latest Antidepressant Efficacy to Optimize Treatment Plans

Paths to Functional Recovery in Major Depressive Disorder: Putting the Patient First – Combining Patient-Centered Care for Major Depressive Disorder with the Latest Antidepressant Efficacy to Optimize Treatment Plans

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 25, 2022
Expires: January 25, 2023
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

Psychiatrists and advanced practice psychiatry clinicians who care for patients with major depressive disorder.

Learning Objectives

  • Incorporate patient preferences, values, and goals when developing a care plan
  • Evaluate patients being treated for MDD to identify the presence of residual symptoms, such as cognitive dysfunction
  • Assess treatment strategies for a patient with MDD that will maximize their quality of life and functional recovery

Activity Description

This is one of two related online multimedia activities designed to assess and enhance clinical decision-making through immersive, interactive learning. Participants will use realistic “near-life” education as they make decisions for what comes next – just like real life.

Statement of Educational Need

Only roughly half of patients with MDD achieve recovery after 6 months of treatment. The others continue to experience residual symptoms that impair their ability to function at work, school, and home. To ensure that more patients with MDD achieve functional recovery, clinicians require practical information about how to provide early, optimized care. In this activity, an expert faculty member will support learners as they are asked to track patients’ response to treatment and detect and manage common residual MDD symptoms. Two cases will be used to illustrate how to individualize MDD care to maximize patients’ chances of recovery.

Learning Goal/Purpose
The goal of this activity is to increase clinicians’ knowledge and competence with regard to optimizing MDD treatment plans, thus increasing the proportion of patients with MDD who are able to achieve functional recovery.

Agenda

  • Prevalence of major depressive disorder since COVID-19 pandemic
  • Functional recovery and the importance of helping patients move beyond symptom remission
  • Case study, functional recovery and shared decision-making
  • Residual symptoms that frequently impede functional recovery
  • Case study, residual symptoms
  • Strategies for managing residual symptoms and responding to insufficient progress toward functional recovery

Faculty

Michael E. Thase, MD
Professor of Psychiatry
Department of Psychiatry
Mood and Anxiety Disorders Treatment and Research Program
Perelman School of Medicine at the University of Pennsylvania
Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Advisory/Consultant: Acadia, Inc.; Akili, Inc.; Alkermes PLC; Allergan, Inc. (Forest, Naurex); Clexio Biosciences, Ltd.; H. Lundbeck, A/S; Jazz Pharmaceuticals; Johnson & Johnson (Janssen); Merck & Company, Inc.; Otsuka Pharmaceutical Company, Ltd.; Pfizer, Inc.; Seelos
Grant Support: Acadia, Inc.; Allergan, Inc.; Axsome Therapeutics Inc.; Intracellular, Inc.; Johnson & Johnson (Janssen); Otsuka Pharmaceutical Company, Ltd.; Patient-Centered Outcomes Research Institute (PCORI); Takeda
Royalties: American Psychiatric Press; Guilford Publications; Herald House; W.W. Norton & Company, Inc.; Wolters Kluwer

CMEology planners have no relationships to disclose.

MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period January 25, 2022 through January 25, 2023, participants must (1) read the learning objectives and faculty disclosures, (2) study the educational activity, (3) complete the posttest by recording the best answer to each question, and (4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: [email protected] or Medical Education Resources at: http://cmepartner.org/contact.

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 25, 2022
Expires: January 25, 2023
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

Psychiatrists and advanced practice psychiatry clinicians who care for patients with major depressive disorder.

Learning Objectives

  • Incorporate patient preferences, values, and goals when developing a care plan
  • Evaluate patients being treated for MDD to identify the presence of residual symptoms, such as cognitive dysfunction
  • Assess treatment strategies for a patient with MDD that will maximize their quality of life and functional recovery

Activity Description

This is one of two related online multimedia activities designed to assess and enhance clinical decision-making through immersive, interactive learning. Participants will use realistic “near-life” education as they make decisions for what comes next – just like real life.

Statement of Educational Need

Only roughly half of patients with MDD achieve recovery after 6 months of treatment. The others continue to experience residual symptoms that impair their ability to function at work, school, and home. To ensure that more patients with MDD achieve functional recovery, clinicians require practical information about how to provide early, optimized care. In this activity, an expert faculty member will support learners as they are asked to track patients’ response to treatment and detect and manage common residual MDD symptoms. Two cases will be used to illustrate how to individualize MDD care to maximize patients’ chances of recovery.

Learning Goal/Purpose
The goal of this activity is to increase clinicians’ knowledge and competence with regard to optimizing MDD treatment plans, thus increasing the proportion of patients with MDD who are able to achieve functional recovery.

Agenda

  • Prevalence of major depressive disorder since COVID-19 pandemic
  • Functional recovery and the importance of helping patients move beyond symptom remission
  • Case study, functional recovery and shared decision-making
  • Residual symptoms that frequently impede functional recovery
  • Case study, residual symptoms
  • Strategies for managing residual symptoms and responding to insufficient progress toward functional recovery

Faculty

Michael E. Thase, MD
Professor of Psychiatry
Department of Psychiatry
Mood and Anxiety Disorders Treatment and Research Program
Perelman School of Medicine at the University of Pennsylvania
Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Advisory/Consultant: Acadia, Inc.; Akili, Inc.; Alkermes PLC; Allergan, Inc. (Forest, Naurex); Clexio Biosciences, Ltd.; H. Lundbeck, A/S; Jazz Pharmaceuticals; Johnson & Johnson (Janssen); Merck & Company, Inc.; Otsuka Pharmaceutical Company, Ltd.; Pfizer, Inc.; Seelos
Grant Support: Acadia, Inc.; Allergan, Inc.; Axsome Therapeutics Inc.; Intracellular, Inc.; Johnson & Johnson (Janssen); Otsuka Pharmaceutical Company, Ltd.; Patient-Centered Outcomes Research Institute (PCORI); Takeda
Royalties: American Psychiatric Press; Guilford Publications; Herald House; W.W. Norton & Company, Inc.; Wolters Kluwer

CMEology planners have no relationships to disclose.

MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period January 25, 2022 through January 25, 2023, participants must (1) read the learning objectives and faculty disclosures, (2) study the educational activity, (3) complete the posttest by recording the best answer to each question, and (4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: [email protected] or Medical Education Resources at: http://cmepartner.org/contact.

0.5 CME / CNE
Medical Education Resources (MER)
Paths to Functional Recovery in Major Depressive Disorder: Putting the Patient First – A Patient-Centered Approach to Preventing, Detecting, and Managing Adverse Effects of Antidepressants

Paths to Functional Recovery in Major Depressive Disorder: Putting the Patient First – A Patient-Centered Approach to Preventing, Detecting, and Managing Adverse Effects of Antidepressants

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 25, 2022
Expires: January 25, 2023
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

Psychiatrists and advanced practice psychiatry clinicians who care for patients with major depressive disorder.

Learning Objectives

  • Evaluate patients being treated for MDD to identify common adverse effects such as sexual dysfunction, weight gain, and sleep disturbance
  • Assess treatment strategies for a patient with MDD who is experiencing an adverse effect on their current MDD therapy

Activity Description

This is one of two related online multimedia activities designed to assess and enhance clinical decision-making through immersive, interactive learning. Participants will use realistic “near-life” education as they make decisions for what comes next – just like real life.

Statement of Educational Need

Adverse effects associated with antidepressants are common. In addition to compromising patients’ health and quality of life, they are one of the most common reasons that individuals with MDD fail to adhere to their treatment plans. To minimize the impact of antidepressant side effects on the lives of patients with MDD, clinicians require education on how to prevent, detect, and manage the most common adverse effects caused by these medications. In this activity, an expert faculty member will support learners as they are asked to respond to patients experiencing side effects related to their antidepressant use. Two cases will be used to illustrate how a patient-centered approach to MDD care can maximize treatment tolerability.

Learning Goal/Purpose
The goal of this activity is to increase clinicians’ knowledge and competence with regard to preventing, detecting, and managing antidepressant side effects, thus minimizing the impact of adverse effects on patients’ lives.

Agenda

  • Prevalence of major antidepressant adverse effects
  • Common adverse effects of antidepressants
  • Case study, sexual dysfunction
  • Case study, weight gain
  • Antidepressant comparative tolerability
  • Strategies for managing antidepressant adverse effects

Faculty

Michael E. Thase, MD
Professor of Psychiatry
Department of Psychiatry
Mood and Anxiety Disorders Treatment and Research Program
Perelman School of Medicine at the University of Pennsylvania
Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Advisory/Consultant: Acadia, Inc.; Akili, Inc.; Alkermes PLC; Allergan, Inc. (Forest, Naurex); Clexio Biosciences, Ltd.; H. Lundbeck, A/S; Jazz Pharmaceuticals; Johnson & Johnson (Janssen); Merck & Company, Inc.; Otsuka Pharmaceutical Company, Ltd.; Pfizer, Inc.; Seelos
Grant Support: Acadia, Inc.; Allergan, Inc.; Axsome Therapeutics Inc.; Intracellular, Inc.; Johnson & Johnson (Janssen); Otsuka Pharmaceutical Company, Ltd.; Patient-Centered Outcomes Research Institute (PCORI); Takeda
Royalties: American Psychiatric Press; Guilford Publications; Herald House; W.W. Norton & Company, Inc.; Wolters Kluwer

CMEology planners have no relationships to disclose.

MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period January 25, 2022 through January 25, 2023, participants must (1) read the learning objectives and faculty disclosures, (2) study the educational activity, (3) complete the posttest

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 25, 2022
Expires: January 25, 2023
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

Psychiatrists and advanced practice psychiatry clinicians who care for patients with major depressive disorder.

Learning Objectives

  • Evaluate patients being treated for MDD to identify common adverse effects such as sexual dysfunction, weight gain, and sleep disturbance
  • Assess treatment strategies for a patient with MDD who is experiencing an adverse effect on their current MDD therapy

Activity Description

This is one of two related online multimedia activities designed to assess and enhance clinical decision-making through immersive, interactive learning. Participants will use realistic “near-life” education as they make decisions for what comes next – just like real life.

Statement of Educational Need

Adverse effects associated with antidepressants are common. In addition to compromising patients’ health and quality of life, they are one of the most common reasons that individuals with MDD fail to adhere to their treatment plans. To minimize the impact of antidepressant side effects on the lives of patients with MDD, clinicians require education on how to prevent, detect, and manage the most common adverse effects caused by these medications. In this activity, an expert faculty member will support learners as they are asked to respond to patients experiencing side effects related to their antidepressant use. Two cases will be used to illustrate how a patient-centered approach to MDD care can maximize treatment tolerability.

Learning Goal/Purpose
The goal of this activity is to increase clinicians’ knowledge and competence with regard to preventing, detecting, and managing antidepressant side effects, thus minimizing the impact of adverse effects on patients’ lives.

Agenda

  • Prevalence of major antidepressant adverse effects
  • Common adverse effects of antidepressants
  • Case study, sexual dysfunction
  • Case study, weight gain
  • Antidepressant comparative tolerability
  • Strategies for managing antidepressant adverse effects

Faculty

Michael E. Thase, MD
Professor of Psychiatry
Department of Psychiatry
Mood and Anxiety Disorders Treatment and Research Program
Perelman School of Medicine at the University of Pennsylvania
Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Advisory/Consultant: Acadia, Inc.; Akili, Inc.; Alkermes PLC; Allergan, Inc. (Forest, Naurex); Clexio Biosciences, Ltd.; H. Lundbeck, A/S; Jazz Pharmaceuticals; Johnson & Johnson (Janssen); Merck & Company, Inc.; Otsuka Pharmaceutical Company, Ltd.; Pfizer, Inc.; Seelos
Grant Support: Acadia, Inc.; Allergan, Inc.; Axsome Therapeutics Inc.; Intracellular, Inc.; Johnson & Johnson (Janssen); Otsuka Pharmaceutical Company, Ltd.; Patient-Centered Outcomes Research Institute (PCORI); Takeda
Royalties: American Psychiatric Press; Guilford Publications; Herald House; W.W. Norton & Company, Inc.; Wolters Kluwer

CMEology planners have no relationships to disclose.

MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period January 25, 2022 through January 25, 2023, participants must (1) read the learning objectives and faculty disclosures, (2) study the educational activity, (3) complete the posttest

1.25 AANP / CME
Global Education Group
Finding the Path in Eosinophilic Esophagitis: Interdisciplinary Strategies for Adult and Pediatric Patients

Finding the Path in Eosinophilic Esophagitis: Interdisciplinary Strategies for Adult and Pediatric Patients

Start

Activity Details

Free CME/AANP
1.25 AMA PRA Category 1 Credit(s)
1.25 AANP contact hour(s)
Released: December 10, 2021
Expires: December 10, 2022
75 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Target Audience

This program is intended for allergists/clinical immunologists, gastroenterologists, and other clinicians involved in the identification and management of patients with eosinophilic esophagitis (EoE).

Program Overview

During this Call-a-Colleague™ program, specialists in allergy/immunology and eosinophilic gastrointestinal disease will discuss the disease burden, pathophysiology, diagnosis, and current management of EoE. Faculty will also present clinical trial evidence for emerging treatment options as well as considerations for patients with other atopic conditions. A unique feature of the program will be the Call-a-Colleague™ sections in which our specialists will elicit additional insight from their multidisciplinary team members, such as a dietitian, a psychologist, and a pediatric gastroenterologist. The clinicians will provide their expertise regarding the mental health burden among patients, the use of an elimination diet to resolve symptoms, and clinical issues pertaining to pediatric patients with EoE.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the pathophysiologic mechanisms underlying EoE development, with a focus on potential therapeutic targets
  • Comprehensively assess pediatric and adult patients with suspected EoE to accelerate differential diagnoses and establish appropriate multidisciplinary care
  • Compare the clinical profiles, available trial evidence, and drawbacks of current and emerging treatment strategies for EoE
  • Longitudinally manage pediatric and adult patients with EoE based on symptoms, comorbidities, updated clinical guidelines, and therapeutic responses
  • Communicate with patients, caregivers, and members of the multidisciplinary team to ensure continuity of care and promote shared clinical decision-making

Faculty

Mirna Chehade, MD, MPH
Associate Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York

Ikuo Hirano, MD
Professor of Medicine (Gastroenterology and Hepatology)
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Jonathan Spergel, MD
Chief, Allergy Program
Children's Hospital of Philadelphia
Stuart E. Starr Chair of Pediatrics
Professor of Pediatrics
Perelman School of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.25 contact hour(s) (which includes 0.0 hour(s) of pharmacology).

Instructions to Receive Credit

In order to receive credit, participants must complete the following:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Preactivity Questions.
  3. Review the activity content.
  4. Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation to receive credit.

Term of Offering

This activity was released on December 10, 2021, and is valid for one year. Requests for credit must be made no later than December 10, 2022.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected]

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Mirna Chehade, MD
Consulting Fee: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc., Bristol Myers Squibb, Ellodi Pharmaceuticals, Phathom Pharmaceuticals Regeneron Pharmaceuticals, Inc., Sanofi S.A, Shire plc, Takeda Pharmaceutical Company Limited.
Contracted Research: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc, Danone S.A., Ellodi Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Shire plc, Takeda Pharmaceutical Company Limited.

Ikuo Hirano, MD
Consultant: Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Avir, Celgene/Receptos/BMS, Eli Lilly, EsoCap, Gossamer Bio, Parexel/Calyx, Regeneron, Shire/Takeda.
Research funding: Adare/Ellodi, Allakos, AstraZeneca, Celgene/Receptos/BMS, Meritage, Regeneron, Shire/Takeda.

Jonathan Spergel, MD
Consultant: Abbott, Novartis, Regeneron, Sanofi.
Research funding: Celgene, Genentech, Novartis, Regeneron, Sanofi.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Kim Rodriguez - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose
Rose O’Connor, PhD, CHCP - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/AANP
1.25 AMA PRA Category 1 Credit(s)
1.25 AANP contact hour(s)
Released: December 10, 2021
Expires: December 10, 2022
75 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Target Audience

This program is intended for allergists/clinical immunologists, gastroenterologists, and other clinicians involved in the identification and management of patients with eosinophilic esophagitis (EoE).

Program Overview

During this Call-a-Colleague™ program, specialists in allergy/immunology and eosinophilic gastrointestinal disease will discuss the disease burden, pathophysiology, diagnosis, and current management of EoE. Faculty will also present clinical trial evidence for emerging treatment options as well as considerations for patients with other atopic conditions. A unique feature of the program will be the Call-a-Colleague™ sections in which our specialists will elicit additional insight from their multidisciplinary team members, such as a dietitian, a psychologist, and a pediatric gastroenterologist. The clinicians will provide their expertise regarding the mental health burden among patients, the use of an elimination diet to resolve symptoms, and clinical issues pertaining to pediatric patients with EoE.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the pathophysiologic mechanisms underlying EoE development, with a focus on potential therapeutic targets
  • Comprehensively assess pediatric and adult patients with suspected EoE to accelerate differential diagnoses and establish appropriate multidisciplinary care
  • Compare the clinical profiles, available trial evidence, and drawbacks of current and emerging treatment strategies for EoE
  • Longitudinally manage pediatric and adult patients with EoE based on symptoms, comorbidities, updated clinical guidelines, and therapeutic responses
  • Communicate with patients, caregivers, and members of the multidisciplinary team to ensure continuity of care and promote shared clinical decision-making

Faculty

Mirna Chehade, MD, MPH
Associate Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York

Ikuo Hirano, MD
Professor of Medicine (Gastroenterology and Hepatology)
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Jonathan Spergel, MD
Chief, Allergy Program
Children's Hospital of Philadelphia
Stuart E. Starr Chair of Pediatrics
Professor of Pediatrics
Perelman School of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.25 contact hour(s) (which includes 0.0 hour(s) of pharmacology).

Instructions to Receive Credit

In order to receive credit, participants must complete the following:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Preactivity Questions.
  3. Review the activity content.
  4. Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation to receive credit.

Term of Offering

This activity was released on December 10, 2021, and is valid for one year. Requests for credit must be made no later than December 10, 2022.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected]

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Mirna Chehade, MD
Consulting Fee: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc., Bristol Myers Squibb, Ellodi Pharmaceuticals, Phathom Pharmaceuticals Regeneron Pharmaceuticals, Inc., Sanofi S.A, Shire plc, Takeda Pharmaceutical Company Limited.
Contracted Research: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc, Danone S.A., Ellodi Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Shire plc, Takeda Pharmaceutical Company Limited.

Ikuo Hirano, MD
Consultant: Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Avir, Celgene/Receptos/BMS, Eli Lilly, EsoCap, Gossamer Bio, Parexel/Calyx, Regeneron, Shire/Takeda.
Research funding: Adare/Ellodi, Allakos, AstraZeneca, Celgene/Receptos/BMS, Meritage, Regeneron, Shire/Takeda.

Jonathan Spergel, MD
Consultant: Abbott, Novartis, Regeneron, Sanofi.
Research funding: Celgene, Genentech, Novartis, Regeneron, Sanofi.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Kim Rodriguez - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose
Rose O’Connor, PhD, CHCP - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.25 CME / CNE
Postgraduate Institute for Medicine
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 6: Neuropsychological and Cognitive Changes

Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 6: Neuropsychological and Cognitive Changes

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: TBD
Expires: TBD
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

  • Tailor antiretroviral therapy (ART) regimens according to patient comorbidities, risk factors, adverse events, and drug−drug interactions

Activity Description

Mental health comorbidities, particularly depression, are common in HIV. Clinicians who treat patients with HIV often lack experience in pharmacologic treatment of depression or other mental health disorders. Dr. Richard A. Elion and Dr. Glenn Jordan Treisman discuss a patient with worsening depression and chronic pain in terms of screening for her depression, the relationship between depression and chronic pain, and both nonpharmacologic and pharmacologic options to treat her depression.

Faculty

Richard A. Elion, MD
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia

Glenn Jordan Treisman, MD, PhD
Director, AIDS Psychiatry Service
Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Richard A. Elion, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., ViiV Healthcare; Other: Work with Trio Health doing research funded by multiple companies

Glenn Jordan Treisman, MD, PhD: Nothing to disclose

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at [email protected] or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at [email protected]

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: TBD
Expires: TBD
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

  • Tailor antiretroviral therapy (ART) regimens according to patient comorbidities, risk factors, adverse events, and drug−drug interactions

Activity Description

Mental health comorbidities, particularly depression, are common in HIV. Clinicians who treat patients with HIV often lack experience in pharmacologic treatment of depression or other mental health disorders. Dr. Richard A. Elion and Dr. Glenn Jordan Treisman discuss a patient with worsening depression and chronic pain in terms of screening for her depression, the relationship between depression and chronic pain, and both nonpharmacologic and pharmacologic options to treat her depression.

Faculty

Richard A. Elion, MD
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia

Glenn Jordan Treisman, MD, PhD
Director, AIDS Psychiatry Service
Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Richard A. Elion, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., ViiV Healthcare; Other: Work with Trio Health doing research funded by multiple companies

Glenn Jordan Treisman, MD, PhD: Nothing to disclose

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at [email protected] or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at [email protected]

0.25 CME / CNE
Postgraduate Institute for Medicine
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 3: HIV in Women

Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 3: HIV in Women

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: December 3, 2021
Expires: December 3, 2022
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

  • Optimize ART regimens and clinical practice to address needs of specific patient populations, such as women with HIV, transgender patients, or patients with substance use disorder

Activity Description

Women with HIV require care outside of traditional HIV management, particularly concerning pregnancy and contraceptives. Clinicians require updates on new data and guidelines about appropriate antiretroviral therapy (ART) regimens during pregnancy as well as strategies for multidisciplinary care. Dr. Chloe Orkin and Dr. Sharon L. Walmsley discuss a patient who is virally suppressed and would like to conceive. They discuss ART regimens, viral monitoring, collaboration with an obstetrician/gynecologist, intra- and postpartum care, breastfeeding, and contraceptives.

Faculty

Chloe Orkin, MBBCH, MSc, FRCP
Consultant Physician and Lead for HIV Research
Professor of HIV Medicine
Queen Mary University of London and Barts Health NHS Trust
Director, SHARE Collaborative
Academic Lead for Equality, Diversity, and Inclusion SMD
President, Medical Women’s Federation
London, United Kingdom


Sharon L. Walmsley, MSc, MD, FRCPC
Director of Clinical Research
Immunodeficiency Clinic
Toronto Hospital, University Health Network
Professor
University of Toronto Department of Medicine
Senior Scientist
Toronto General Hospital Research Institute
Co-Chair of the CIHR Canadian HIV Trials Network
Toronto, Ontario, Canada

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Chloe Orkin, MBBCH, MSc, FRCP: Consulting Fees: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare

Sharon L. Walmsley, MSc, MD, FRCPC: Consulting Fees: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck & Co., Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., ViiV Healthcare

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at [email protected] or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at [email protected]

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: December 3, 2021
Expires: December 3, 2022
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

  • Optimize ART regimens and clinical practice to address needs of specific patient populations, such as women with HIV, transgender patients, or patients with substance use disorder

Activity Description

Women with HIV require care outside of traditional HIV management, particularly concerning pregnancy and contraceptives. Clinicians require updates on new data and guidelines about appropriate antiretroviral therapy (ART) regimens during pregnancy as well as strategies for multidisciplinary care. Dr. Chloe Orkin and Dr. Sharon L. Walmsley discuss a patient who is virally suppressed and would like to conceive. They discuss ART regimens, viral monitoring, collaboration with an obstetrician/gynecologist, intra- and postpartum care, breastfeeding, and contraceptives.

Faculty

Chloe Orkin, MBBCH, MSc, FRCP
Consultant Physician and Lead for HIV Research
Professor of HIV Medicine
Queen Mary University of London and Barts Health NHS Trust
Director, SHARE Collaborative
Academic Lead for Equality, Diversity, and Inclusion SMD
President, Medical Women’s Federation
London, United Kingdom


Sharon L. Walmsley, MSc, MD, FRCPC
Director of Clinical Research
Immunodeficiency Clinic
Toronto Hospital, University Health Network
Professor
University of Toronto Department of Medicine
Senior Scientist
Toronto General Hospital Research Institute
Co-Chair of the CIHR Canadian HIV Trials Network
Toronto, Ontario, Canada

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Chloe Orkin, MBBCH, MSc, FRCP: Consulting Fees: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare

Sharon L. Walmsley, MSc, MD, FRCPC: Consulting Fees: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck & Co., Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., ViiV Healthcare

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at [email protected] or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at [email protected]

0.25 CME / CNE
Postgraduate Institute for Medicine
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 5: Controversies in Managing Resistance

Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 5: Controversies in Managing Resistance

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: December 3, 2021
Expires: December 3, 2022
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

  • Address the challenges faced when selecting subsequent ART regimens in patients experiencing virologic failure

Activity Description

Though first-line antiretroviral therapy (ART) regimens have high barriers to resistance, it is still important to obtain genotyping for newly diagnosed patients and for those experiencing virologic failure. There is evidence that patients with a variety of resistance mutations can still achieve viral suppression, though regimen selection may be influenced by resistance mutations. Dr. Richard A. Elion and Dr. Jürgen Rockstroh discuss a newly diagnosed patient with baseline resistance mutations in the context of treatment initiation, switching, impact of specific mutations, and how resistance mutations influence selection of either 2-drug or long-acting therapies.

Faculty

Richard A. Elion, MD
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia


Jürgen Rockstroh, MD
Professor of Medicine
Head of the HIV Outpatient Clinic
University of Bonn
Bonn, Germany

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Richard A. Elion, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., ViiV Healthcare; Other: Work with Trio Health doing research funded by multiple companies

Jürgen Rockstroh, MD: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., Theratechnologies Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at [email protected] or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at [email protected]

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: December 3, 2021
Expires: December 3, 2022
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

  • Address the challenges faced when selecting subsequent ART regimens in patients experiencing virologic failure

Activity Description

Though first-line antiretroviral therapy (ART) regimens have high barriers to resistance, it is still important to obtain genotyping for newly diagnosed patients and for those experiencing virologic failure. There is evidence that patients with a variety of resistance mutations can still achieve viral suppression, though regimen selection may be influenced by resistance mutations. Dr. Richard A. Elion and Dr. Jürgen Rockstroh discuss a newly diagnosed patient with baseline resistance mutations in the context of treatment initiation, switching, impact of specific mutations, and how resistance mutations influence selection of either 2-drug or long-acting therapies.

Faculty

Richard A. Elion, MD
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia


Jürgen Rockstroh, MD
Professor of Medicine
Head of the HIV Outpatient Clinic
University of Bonn
Bonn, Germany

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Richard A. Elion, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., ViiV Healthcare; Other: Work with Trio Health doing research funded by multiple companies

Jürgen Rockstroh, MD: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., Theratechnologies Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at [email protected] or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at [email protected]

0.25 CME / CNE
Postgraduate Institute for Medicine
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 4: Heavily Treatment-Experienced Patients

Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 4: Heavily Treatment-Experienced Patients

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: December 3, 2021
Expires: December 3, 2022
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Address the challenges faced when selecting subsequent ART regimens in patients experiencing virologic failure
  • Review recent data on new and emerging ART regimens

Activity Description

As patients with HIV live longer, clinicians must work with heavily treatment-experienced patients who are experiencing virologic failure and have few treatment options left. Though this is a small population, their subsequent antiretroviral therapy (ART) regimens should be tailored carefully and may need to employ new ART agents as they become available. Dr. Chloe Orkin and Dr. Jonathan Schapiro discuss a heavily treatment-experienced patient in the context of resistance mutations, Stanford score, considerations for subsequent regimens, and new and emerging options for these patients.

Faculty

Chloe Orkin, MBBCH, MSc, FRCP
Consultant Physician and Lead for HIV Research
Professor of HIV Medicine
Queen Mary University of London and Barts Health NHS Trust
Director, SHARE Collaborative
Academic Lead for Equality, Diversity, and Inclusion SMD
President, Medical Women’s Federation
London, United Kingdom


Jonathan Schapiro, MD
Director
HIV/AIDS Clinic
National Hemophilia Center
Sheba Medical Center
Tel Aviv, Israel

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Chloe Orkin, MBBCH, MSc, FRCP: Consulting Fees: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare

Jonathan Schapiro, MD: Consulting Fees: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education; Contracted Research: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education; Speakers Bureau: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at [email protected] or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at [email protected]

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: December 3, 2021
Expires: December 3, 2022
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Address the challenges faced when selecting subsequent ART regimens in patients experiencing virologic failure
  • Review recent data on new and emerging ART regimens

Activity Description

As patients with HIV live longer, clinicians must work with heavily treatment-experienced patients who are experiencing virologic failure and have few treatment options left. Though this is a small population, their subsequent antiretroviral therapy (ART) regimens should be tailored carefully and may need to employ new ART agents as they become available. Dr. Chloe Orkin and Dr. Jonathan Schapiro discuss a heavily treatment-experienced patient in the context of resistance mutations, Stanford score, considerations for subsequent regimens, and new and emerging options for these patients.

Faculty

Chloe Orkin, MBBCH, MSc, FRCP
Consultant Physician and Lead for HIV Research
Professor of HIV Medicine
Queen Mary University of London and Barts Health NHS Trust
Director, SHARE Collaborative
Academic Lead for Equality, Diversity, and Inclusion SMD
President, Medical Women’s Federation
London, United Kingdom


Jonathan Schapiro, MD
Director
HIV/AIDS Clinic
National Hemophilia Center
Sheba Medical Center
Tel Aviv, Israel

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Chloe Orkin, MBBCH, MSc, FRCP: Consulting Fees: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare

Jonathan Schapiro, MD: Consulting Fees: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education; Contracted Research: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education; Speakers Bureau: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at [email protected] or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at [email protected]

0.25 CME / MOC
RMEI Medical Education, LLC
Cases in NTM-LD: Treating Refractory MAC and Mitigating Adverse Events

Cases in NTM-LD: Treating Refractory MAC and Mitigating Adverse Events

Start
Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: November 24, 2021
Expires: November 23, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for pulmonology and infectious disease clinicians (MD/NP/PA) who manage patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Develop personalized treatment strategies for NTM-LD based on current data, guidelines, and best practices
  • Integrate the unique roles and responsibilities of the interprofessional care team members when managing NTM-LD

Activity Description

In this 15-minute activity, an expert panel comprised of 2 pulmonologists and a pulmonology advanced practice provider discuss the management of 2 challenging cases of Mycobacterium avium complex (MAC) lung disease. The panel will provide privileged insights into strategies for controlling refractory MAC lung disease, highlighting their unique roles in the interprofessional management of treatment-related adverse events.

Faculty

Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Charles L. Daley, MD
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Professor, Medicine
National Jewish Health, the University of Colorado and Icahn School of Medicine at Mt. Sinai
Denver, CO

Tara Sadler, APRN, MSN, FNP-C
Advanced Practice Provider
Pulmonary Clinic
University of Texas at Tyler Health Science Center
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Charles L. Daley, MD, has financial relationships with AN2, Insmed, Matinas, Paratek, Spero (Advisor); BugWorks, Insmed, Paratek (Grant/Research Support).

Julie V. Philley, MD, has financial relationships with AN2, Electromed, Paratek (Consultant); AN2, Electromed, Hillrom, Insmed, Paratek, RedHill, Regeneron, Zambon (Researcher); France Foundation, Insmed (Speaker’s Bureau).

Tara Sadler, APRN, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.


American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected]

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 67% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: November 24, 2021
Expires: November 23, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for pulmonology and infectious disease clinicians (MD/NP/PA) who manage patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Develop personalized treatment strategies for NTM-LD based on current data, guidelines, and best practices
  • Integrate the unique roles and responsibilities of the interprofessional care team members when managing NTM-LD

Activity Description

In this 15-minute activity, an expert panel comprised of 2 pulmonologists and a pulmonology advanced practice provider discuss the management of 2 challenging cases of Mycobacterium avium complex (MAC) lung disease. The panel will provide privileged insights into strategies for controlling refractory MAC lung disease, highlighting their unique roles in the interprofessional management of treatment-related adverse events.

Faculty

Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Charles L. Daley, MD
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Professor, Medicine
National Jewish Health, the University of Colorado and Icahn School of Medicine at Mt. Sinai
Denver, CO

Tara Sadler, APRN, MSN, FNP-C
Advanced Practice Provider
Pulmonary Clinic
University of Texas at Tyler Health Science Center
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Charles L. Daley, MD, has financial relationships with AN2, Insmed, Matinas, Paratek, Spero (Advisor); BugWorks, Insmed, Paratek (Grant/Research Support).

Julie V. Philley, MD, has financial relationships with AN2, Electromed, Paratek (Consultant); AN2, Electromed, Hillrom, Insmed, Paratek, RedHill, Regeneron, Zambon (Researcher); France Foundation, Insmed (Speaker’s Bureau).

Tara Sadler, APRN, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.


American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected]

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 67% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.25 CME / MOC
RMEI Medical Education, LLC
Challenging Cases in NTM-LD: Refractory MAC and Medication Intolerance

Challenging Cases in NTM-LD: Refractory MAC and Medication Intolerance

Start
Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: November 24, 2021
Expires: November 23, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for pulmonology and infectious disease clinicians (MD/NP/PA) who manage patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Develop personalized treatment strategies for NTM-LD based on current data, guidelines, and best practices
  • Integrate the unique roles and responsibilities of the interprofessional care team members when managing NTM-LD

Activity Description

In this 15-minute activity, an expert panel comprised of 2 pulmonologists and a pulmonology advanced practice provider discuss the management of 2 challenging cases involving Mycobacterium avium complex (MAC) lung disease. The panel will provide privileged insights into the application of evidence and guideline-based treatment for refractory MAC lung disease, highlighting their unique roles in the interprofessional management of medication intolerance.

Faculty

Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Charles L. Daley, MD
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Professor, Medicine
National Jewish Health, the University of Colorado and Icahn School of Medicine at Mt. Sinai
Denver, CO

Tara Sadler, APRN, MSN, FNP-C
Advanced Practice Provider
Pulmonary Clinic
University of Texas at Tyler Health Science Center
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Charles L. Daley, MD, has financial relationships with AN2, Insmed, Matinas, Paratek, Spero (Advisor); BugWorks, Insmed, Paratek (Grant/Research Support).

Julie V. Philley, MD, has financial relationships with AN2, Electromed, Paratek (Consultant); AN2, Electromed, Hillrom, Insmed, Paratek, RedHill, Regeneron, Zambon (Researcher); France Foundation, Insmed (Speaker’s Bureau).

Tara Sadler, APRN, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.


American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected]

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 67% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: November 24, 2021
Expires: November 23, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for pulmonology and infectious disease clinicians (MD/NP/PA) who manage patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Develop personalized treatment strategies for NTM-LD based on current data, guidelines, and best practices
  • Integrate the unique roles and responsibilities of the interprofessional care team members when managing NTM-LD

Activity Description

In this 15-minute activity, an expert panel comprised of 2 pulmonologists and a pulmonology advanced practice provider discuss the management of 2 challenging cases involving Mycobacterium avium complex (MAC) lung disease. The panel will provide privileged insights into the application of evidence and guideline-based treatment for refractory MAC lung disease, highlighting their unique roles in the interprofessional management of medication intolerance.

Faculty

Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Charles L. Daley, MD
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Professor, Medicine
National Jewish Health, the University of Colorado and Icahn School of Medicine at Mt. Sinai
Denver, CO

Tara Sadler, APRN, MSN, FNP-C
Advanced Practice Provider
Pulmonary Clinic
University of Texas at Tyler Health Science Center
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Charles L. Daley, MD, has financial relationships with AN2, Insmed, Matinas, Paratek, Spero (Advisor); BugWorks, Insmed, Paratek (Grant/Research Support).

Julie V. Philley, MD, has financial relationships with AN2, Electromed, Paratek (Consultant); AN2, Electromed, Hillrom, Insmed, Paratek, RedHill, Regeneron, Zambon (Researcher); France Foundation, Insmed (Speaker’s Bureau).

Tara Sadler, APRN, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.


American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected]

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 67% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Pages